OpenAlex
PricingAboutJobs
Log inGet started
Work

Results of a Phase I dose-escalating study of the antiangiogenic agent, SU5416, in patients with advanced malignancies.

PubMed

Year: 2002
Type: article
Study design: Clinical Trial
Source: PubMed
Authors: Alison Stopeck, Marrae Sheldon, Mahmood Vahedian, Gillian Cropp, Rishi Gosalia, Alison Hannah
Institutions: University of Arizona, Pfizer (United States), Pfizer (United Kingdom)
Language: English

Topic: Angiogenesis and VEGF in Cancer
Subfield: Molecular Biology
Field: Biochemistry, Genetics and Molecular Biology
Domain: Life Sciences
Keywords: SU5416, sunitinib, anti-angiogenic therapy, vascular endothelial growth factor, dose escalation, pharmacokinetics, drug toxicity, headache, predictive biomarkers, advanced cancer, gastrointestinal cancer, breast cancer, lung cancer, sarcoma
SDG: Good health and well-being

Open Access status: closed
OpenAlex ID: W2155424478
FWCI: 6.435
Cites: 46
Cited by: 156
Related to: 10
OpenAlex
Nonprofit
Open DataOpen Data
Open Source
Product
Search
Compare
Pricing
Repositories
Unpaywall
Unsub
Developers
API docs
Data snapshot
Status
Source code
Organization
About
Team
Testimonials
Brand
Jobs
Community
Help center
Contact
Events
Blog
Mailing list
Supporters
Legal
Privacy
Accessibility
Terms